Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|February 26, 2009
Draft Guidance Issued for Influenza Drug Development
Author(s)Pharmaceutical Technology Editors
The US Food and Drug Administration has released a draft guidance for industry entitled Influenza: Developing Drugs for Treatment and/or Prophylaxis.
Advertisement
Rockville, MD (Feb. 19)-The US Food and Drug Administration released a draft guidance for industry titled Influenza: Developing Drugs for Treatment and/or Prophylaxis. This document aims to assist companies in all phases of influenza drug development by addressing common questions the agency often receives regarding the potential for the emergency use of influenza drugs. FDA developed the draft in response to recent concerns regarding pandemic influenza and the ongoing public health risks of seasonal influenza.
The document covers preclinical development, early-phase clinical development, and Phase III protocol designs and endpoints specific to influenza A and influenza B drugs. The draft also discusses the role of animal studies as part of drug development, emphasizing that cell culture and animal-model studies can make valuable contributions to clinical-trial design. The document also describes considerations relating to the potential for emergency use of influenza drugs.
FDA will receive comments about the draft until May 21, 2009.
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement